



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/603,000	06/23/2003	David S. F. Young	2056.020	1632
7590	10/02/2006			
Michael A. Slavin McHale & Slavin, P.A. 2855 PGA Boulevard Palm Beach Gardens, FL 33410				EXAMINER BLANCHARD, DAVID J
			ART UNIT 1643	PAPER NUMBER

DATE MAILED: 10/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary	Application No.	Applicant(s)
	10/603,000	YOUNG ET AL.
	Examiner David J. Blanchard	Art Unit 1643

All participants (applicant, applicant's representative, PTO personnel):

(1) David J. Blanchard.

(3) _____.

(2) Ferris Lander.

(4) _____.

Date of Interview: 16 August 2006.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: All pending.

Identification of prior art discussed: N/A.


Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Discussed proposed claim amendments and possible rejoinder of process claims in view of the allowable product claims. The examiner requested clarification on the term "cellular cytotoxicity" and the ability of the claimed antigen-binding fragments to mediate "cellular cytotoxicity", particularly complement activation and antibody dependent cellular cytotoxicity as claims to antigen-binding fragments, which lack the Fc region of the antibody responsible for mediating complement activation and antibody dependent cellular cytotoxicity raise an enablement issue under the first paragraph of 35 U.S.C. 112. Further, it was noted that antigen-binding fragments would not be produced by the claimed hybridoma (PTA-4621) as claimed, but could be produced from the isolated antibody produced by the hybridoma PTA-4621.